Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Nkarta (NASDAQ:NKTX), a clinical-stage biopharmaceutical company focused on engineered natural killer (NK) cell therapies, has announced its participation in the upcoming H.C. Wainwright "HCW@Home" Series. The company will engage in a fireside chat on July 30, 2025, at 11:00 a.m. ET.
Investors can access the webcast through registration or via the Investors section of Nkarta's website. A replay will be available on www.nkartatx.com for approximately 90 days following the event.
Nkarta (NASDAQ:NKTX), un'azienda biofarmaceutica in fase clinica specializzata in terapie con cellule natural killer (NK) ingegnerizzate, ha annunciato la sua partecipazione alla prossima serie "HCW@Home" organizzata da H.C. Wainwright. L'azienda prenderà parte a una conversazione informale il 30 luglio 2025 alle 11:00 ET.
Gli investitori potranno seguire il webcast registrandosi o tramite la sezione Investitori del sito web di Nkarta. Una replica sarà disponibile su www.nkartatx.com per circa 90 giorni dopo l'evento.
Nkarta (NASDAQ:NKTX), una compañía biofarmacéutica en etapa clínica enfocada en terapias con células natural killer (NK) modificadas, ha anunciado su participación en la próxima serie "HCW@Home" de H.C. Wainwright. La empresa participará en una charla informal el 30 de julio de 2025 a las 11:00 a.m. ET.
Los inversores podrán acceder a la transmisión en vivo mediante registro o a través de la sección de Inversores en el sitio web de Nkarta. Una repetición estará disponible en www.nkartatx.com durante aproximadamente 90 días después del evento.
Nkarta (NASDAQ:NKTX)는 엔지니어링된 자연 살해(NK) 세포 치료에 중점을 둔 임상 단계 바이오제약 회사로, 다가오는 H.C. Wainwright의 "HCW@Home" 시리즈에 참여한다고 발표했습니다. 회사는 2025년 7월 30일 오전 11시(동부시간)에 화기애애한 대화를 진행할 예정입니다.
투자자들은 등록을 통해 또는 Nkarta 웹사이트의 투자자 섹션에서 웹캐스트에 접속할 수 있습니다. 이벤트 후 약 90일간 www.nkartatx.com에서 다시보기가 제공됩니다.
Nkarta (NASDAQ:NKTX), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies par cellules tueuses naturelles (NK) modifiées, a annoncé sa participation à la prochaine série "HCW@Home" organisée par H.C. Wainwright. La société participera à une discussion informelle le 30 juillet 2025 à 11h00 ET.
Les investisseurs peuvent accéder au webcast en s'inscrivant ou via la section Investisseurs du site web de Nkarta. Une rediffusion sera disponible sur www.nkartatx.com pendant environ 90 jours après l'événement.
Nkarta (NASDAQ:NKTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf entwickelte natürliche Killerzellen (NK) Therapien spezialisiert hat, hat seine Teilnahme an der bevorstehenden H.C. Wainwright "HCW@Home" Serie angekündigt. Das Unternehmen wird an einem Gespräch am 30. Juli 2025 um 11:00 Uhr ET teilnehmen.
Investoren können über eine Registrierung oder über den Investor-Bereich auf der Website von Nkarta auf das Webcast zugreifen. Eine Wiederholung wird für etwa 90 Tage nach der Veranstaltung auf www.nkartatx.com verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series.
H.C Wainwright “HCW@Home with Nkarta, Inc.”
July 30, 2025
11:00 a.m. ET – fireside chat
Register for the webcast here. A simultaneous webcast of the event will also be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com
FAQ
When is Nkarta (NKTX) presenting at the H.C. Wainwright conference?
How can investors access Nkarta's (NKTX) H.C. Wainwright presentation?
How long will the replay of Nkarta's (NKTX) presentation be available?
What type of therapies is Nkarta (NKTX) developing?
